Covant is focused on autoimmune diseases primarily mediated by IgG.
We are developing a first-in-class oral FcRn inhibitor and a best-in-class long-acting injectable that will offer advantages over approved injectable biologics.
FcRn
The neonatal Fc recptor (FcRn) is a cell surface protein that plays a critical role in the trafficking and homestatic regulation of immunoglobulin G (IgG).
While autoimmune disorders are multifactorial in origin, pathogenic IgG autoantibodies are strongly implicated in the pathogenesis of many of these conditions.
FcRn does not distinguish between pathogenic and non-pathogenic IgG during the recycling process; consequently, pathogenic IgG is preserved in the circulation alongside normal IgG, thereby perpetuating autoimmune disease activity.
Validated Therapeutic Strategy
Injectable FcRn inhibitors have received regulatory approval for the treatment of generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and immune thrombocytopenia. Injectables have laid the groundwork for indication proofs of concept such that there is a fast path forward for oral and longer acting injectable agents in the FcRn space.
Oral Delivery
The convenience of oral FcRn inhibitors may offer route of administration and combination advantages, facilitate earlier intervention, and broaden the spectrum of patients who can benefit from targeted IgG-lowering treatments.
